Abstract Library

#4630 Radiolabelled somatostatin receptor (SSTR) antagonist vs. agonist for peptide receptor radionuclide therapy (PPRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study

Introduction: PRRT with lutetium-177 labelled somatostatin receptor (SSTR) agonists ([177Lu]Lu-DOTATATE or [177Lu]Lu-DOTATOC (177Lu-TOC) has limited response rate and durability. The SSTR antagonist [177Lu]Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses with better efficacy.

Conference:

Presenting Author: Eigler C

Authors: Eigler C, Mushaweh A, McDougall L, Bauman A, Christ E,

Keywords: Somatostatin Receptor, Neuroendocrine Tumour, DOTA-JR11, DOTA-TOC, Peptide Receptor Radionuclide Therapy,

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4045 Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small intestinal neuroendocrine tumors – A Phase II surgical trial

Introduction: Radio-guided surgery (RGS) proved to be promising in neuroendocrine tumors (NETs). Previous studies showed high sensitivity but low specificity using gamma probes to detect radiation emitted by radio-labelled somatostatin analogues.

Conference:

Presenting Author: Danieli M

Authors: Bertani E, Fumagalli Romario U, Collamati F, Mattana F, Fazio N,

Keywords: Radio-guided surgery, small-intestinal neuroendocrine tumor, small-intestinal resection, beta-probe, radiolabelled somatostatine analogues, surgery, lymphadenectomy,

#3825 Ga-68 DOTA-TOC PET/CT uptake by the parathyroid glands in patients with multiple endocrine neoplasia type 1 (MEN1)

Introduction: Primary hyperparathyroidism (PHPT) is the most common manifestation of MEN1. While Ga-68 DOTA-TOC PET/CT (GaPET) is increasingly used in this cohort for assessment of neuroendocrine tumors (NETs), there are limited data on its utility in assessing parathyroid disease.

Conference:

Presenting Author: Storan D

Authors: Storan D, Flynn S, O'Toole D, Almeamar H, O'Shea D,

Keywords: MEN1, PET CT, Gallium, Parathyroid,